Logo image of GANX

GAIN THERAPEUTICS INC (GANX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GANX - US36269B1052 - Common Stock

2.44 USD
+0.03 (+1.24%)
Last: 1/8/2026, 12:08:57 PM
Fundamental Rating

1

GANX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. GANX has a bad profitability rating. Also its financial health evaluation is rather negative. GANX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GANX has reported negative net income.
GANX had a negative operating cash flow in the past year.
In the past 5 years GANX always reported negative net income.
GANX had a negative operating cash flow in each of the past 5 years.
GANX Yearly Net Income VS EBIT VS OCF VS FCFGANX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of GANX (-168.36%) is worse than 86.04% of its industry peers.
GANX has a worse Return On Equity (-278.10%) than 71.70% of its industry peers.
Industry RankSector Rank
ROA -168.36%
ROE -278.1%
ROIC N/A
ROA(3y)-120.33%
ROA(5y)-86.78%
ROE(3y)-182.77%
ROE(5y)-129.19%
ROIC(3y)N/A
ROIC(5y)N/A
GANX Yearly ROA, ROE, ROICGANX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

GANX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GANX Yearly Profit, Operating, Gross MarginsGANX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

3

2. Health

2.1 Basic Checks

GANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
GANX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, GANX has more shares outstanding
GANX has a worse debt/assets ratio than last year.
GANX Yearly Shares OutstandingGANX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
GANX Yearly Total Debt VS Total AssetsGANX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -2.53, we must say that GANX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of GANX (-2.53) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.04 indicates that GANX is not too dependend on debt financing.
The Debt to Equity ratio of GANX (0.04) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -2.53
ROIC/WACCN/A
WACC8.79%
GANX Yearly LT Debt VS Equity VS FCFGANX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 2.97 indicates that GANX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.97, GANX is doing worse than 64.72% of the companies in the same industry.
GANX has a Quick Ratio of 2.97. This indicates that GANX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of GANX (2.97) is worse than 62.26% of its industry peers.
Industry RankSector Rank
Current Ratio 2.97
Quick Ratio 2.97
GANX Yearly Current Assets VS Current LiabilitesGANX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 47.86% over the past year.
GANX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)47.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.76%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GANX will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.02% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.49%
EPS Next 2Y10.09%
EPS Next 3Y-0.26%
EPS Next 5Y10.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GANX Yearly Revenue VS EstimatesGANX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2029 2030 2031 2032 100M 200M 300M
GANX Yearly EPS VS EstimatesGANX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GANX. In the last year negative earnings were reported.
Also next year GANX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GANX Price Earnings VS Forward Price EarningsGANX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GANX Per share dataGANX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.09%
EPS Next 3Y-0.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GANX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

GAIN THERAPEUTICS INC

NASDAQ:GANX (1/8/2026, 12:08:57 PM)

2.44

+0.03 (+1.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-25 2026-03-25/amc
Inst Owners11.31%
Inst Owner Change0%
Ins Owners2.61%
Ins Owner Change0%
Market Cap93.84M
Revenue(TTM)N/A
Net Income(TTM)-20.41M
Analysts85.45
Price Target7.75 (217.62%)
Short Float %5.58%
Short Ratio1.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.83%
Min EPS beat(2)22.48%
Max EPS beat(2)41.18%
EPS beat(4)3
Avg EPS beat(4)-3.99%
Min EPS beat(4)-105.88%
Max EPS beat(4)41.18%
EPS beat(8)4
Avg EPS beat(8)-13.95%
EPS beat(12)6
Avg EPS beat(12)-8.59%
EPS beat(16)8
Avg EPS beat(16)-12.45%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.31%
PT rev (3m)-1.48%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-0.26%
EPS NY rev (3m)1.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.79
P/tB 13.02
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0
BVpS0.19
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -168.36%
ROE -278.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.33%
ROA(5y)-86.78%
ROE(3y)-182.77%
ROE(5y)-129.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.97
Quick Ratio 2.97
Altman-Z -2.53
F-Score1
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)81.72%
Cap/Depr(5y)179.04%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.76%
EPS Next Y28.49%
EPS Next 2Y10.09%
EPS Next 3Y-0.26%
EPS Next 5Y10.02%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.04%
OCF growth 3YN/A
OCF growth 5YN/A

GAIN THERAPEUTICS INC / GANX FAQ

Can you provide the ChartMill fundamental rating for GAIN THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to GANX.


What is the valuation status of GAIN THERAPEUTICS INC (GANX) stock?

ChartMill assigns a valuation rating of 0 / 10 to GAIN THERAPEUTICS INC (GANX). This can be considered as Overvalued.


Can you provide the profitability details for GAIN THERAPEUTICS INC?

GAIN THERAPEUTICS INC (GANX) has a profitability rating of 0 / 10.


Can you provide the financial health for GANX stock?

The financial health rating of GAIN THERAPEUTICS INC (GANX) is 3 / 10.


What is the earnings growth outlook for GAIN THERAPEUTICS INC?

The Earnings per Share (EPS) of GAIN THERAPEUTICS INC (GANX) is expected to grow by 28.49% in the next year.